Support Authera to apply for WomenTech EU

Neovascular age-related macular degeneration (nAMD) is a leading cause of vision loss, estimated to affect >50M by 2040. However, up to 40% of patients do not respond well to current treatments or develop resistance over time, driving the need for new options. To meet this need, Authera develops a therapeutic antibody targeting a new target with tailored mode-of-action. Our solution offers a new strategy to that of competitors. An already awarded IPN grant from the RCN together with SkatteFUNN partially fund the R&D activities of the first three year of our antibody development program. However, to succeed as a deep tech company, the Womentech EU grant is needed to support critical activities related to organization building, business development and establishment of an investor strategy to improve our business-readiness level. Simone Mester (CEO) and the biotechnology start-up Authera are applying to WomenTech EU as their first EU grant. As such, we are applying for PES to get support to cover our expenses related to the application process.